Atrial Fibrillation in 2025: From wearables to phenotype
Dr Jamie Voss and Dr Anthony Kueh
Learning aims:
- Interpret common presentations of wearable-detected atrial fibrillation.
- Apply strategies for upstream AF prevention and risk factor modification.
- Explain the use of CHA₂DS₂-VA score in guiding anticoagulation decisions.
- Choose appropriate rhythm control strategies based on patient phenotype.
ECG Challenge
Dr David Heaven and Dr Nezar Amir
Learning aims:
- Interpret a range of ECGs with clinically relevant arrhythmias.
- Recognise and explain the significance common abnormalities such as prolongation of the QT interval.
Genetic Cardiac Conditions: Who needs screening and when
Dr Andrew Martin and Dr Ivor Gerber
Learning aims:
- Review the principles of screening genetic cardiac conditions. When and Who?
- What are implications of screening?
- Common conditions where screening may be recommended : HCM, DCM, Aortopathies, Bicuspid aortic valve.
IntraCare and The Heart Group Showcase
Jeanette Kini, Dr Jith Somaratne, Dr Jonathon White and Dr Andrew Martin
Learning aims:
- Describe recent changes in referrals and care patterns at IntraCare.
- Demonstrate how to access and apply INTRA and THG resources in clinical practice.
Medical Aspects of Fitness to Drive – A chance to question the co-authors
Assoc Prof Nigel Lever and Dr Cara Wasywich
Learning aims:
- Describe clinician responsibilities under the 2024 guidance on fitness to drive.
- Summarise licensing requirements across vehicle classes (1/6 vs 2–5 / P endorsement).
- Practice how to discuss driving cessation with patients compassionately and effectively.
Heart Failure in Special Populations: Renal impairment and the Elderly
Dr Michael Stubbs and Dr Tom Pasley
Learning aims:
- Apply principles of safe heart failure prescribing in patients with renal impairment.
- Evaluate when to continue or deprescribe heart failure medications in older adults.
- Define destination medical therapy and its relevance in elderly heart failure care.
Orthostatic Intolerance in the Young: Key Messages for GPs
Dr Ross Nicholson and Dr Fiona Stewart
Learning aims:
- Review a systematic approach to diagnosis and appropriate investigations.
- Review the initial non-pharmacological management strategies.
- How to select the right pharmacologic agents for the patient's symptoms.
Weight Loss Drugs Debate – Cardiovascular Benefit First?
Dr Jeffrey Sebastian, Dr Shakiya Ershad, Dr Sarah Fitzsimons and Dr Ruvin Gabriel. Debate Chair: Dr Wil Harrison
Motion: “This house believes that the primary indication for GLP-1 agonists should be cardiovascular benefit.”
Learning aims:
- Compare the cardiovascular and metabolic benefits of GLP-1 agonists.
- Evaluate the evidence supporting cardiovascular indications for weight loss drugs.
- Discuss readiness for broader implementation of these therapies in Aotearoa New Zealand.
The Heart Group
